{"id":89478,"date":"2024-10-14T10:07:24","date_gmt":"2024-10-14T08:07:24","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=89478"},"modified":"2024-10-14T10:07:24","modified_gmt":"2024-10-14T08:07:24","slug":"inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/","title":{"rendered":"Inventiva announces financing of up to \u20ac348 million to advance the NATiV3 Phase 3 MASH study"},"content":{"rendered":"<p><span class=\"Apple-converted-space\">\u00a0<\/span>Inventiva (Euronext Paris and Nasdaq: IVA) (\u201c<b>Inventiva<\/b>\u201d or the \u201c<b>Company<\/b>\u201d), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (\u201c<b>MASH<\/b>\u201d) and other diseases with significant unmet medical needs, today announced financing of immediately \u20ac94.1 million and up to \u20ac348 million (the \u201c<b>Transaction<\/b>\u201d), subject to satisfaction of specified conditions, to fund the completion of the Phase 3 NATiV3 MASH trial and preparation for the potential filing for marketing approval and commercialization of lanifibranor.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>The Transaction was led by New Enterprise Associates, BVF Partners LP and Samsara BioCapital, with the participation of additional existing and new investors including Andera Partners, Deep Track Capital, Eventide Asset Management, Great Point Partners, LLC, Invus, Perceptive Advisors, Schonfeld Strategic Advisors and Sofinnova Crossover I SLP.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Pursuant to the Transaction and subject to shareholder approval at the next general meeting to be convened by December 16, 2024, the Company appointed Mark Pruzanski, MD, as Company Chairman, and Srinivas Akkaraju, MD, PhD, as a director. Up to four additional directors are to be named by each of the other four largest investors, of whom at least two will qualify as independent and would replace existing directors (excluding Frederic Cren, Mark Pruzanski and Srini Akkaraju).<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p><b>Dr. Mark Pruzanski said: <\/b>\u201c<i>I have long believed in the therapeutic potential of lanifibranor in MASH and am honored at the prospect of joining Inventiva as Chairman. Based on the previously published Phase 2b NATIVE study results, lanifibranor has a profile that positions it as a possible \u2018best in category\u2019 oral drug: its insulin sensitizing and direct antifibrotic benefits make it an ideal therapy for the large population of Type 2 diabetic patients with advanced fibrosis due to MASH who are at the greatest risk of progressing to liver failure. With the support of the equivalent<span class=\"Apple-converted-space\">\u00a0<\/span><\/i><i>of up to $410 million in funding announced today, I look forward to working with Frederic and the rest of the Board to help transition the Company to maximize its ability to deliver on lanifibranor\u2019s promise<\/i>.\u201d<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>J.P. Morgan, TD Cowen, Guggenheim Securities, and LifeSci Capital are acting as placement agents for the financing, and Namsen Capital is acting as Equity Capital Markets Advisor.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p><b>Frederic Cren, Chief Executive Officer of Inventiva, stated: <\/b><i>&#8220;I am very pleased to announce this important financing at a critical juncture for the Company. This reflects the confidence of the participating investors and our partner CTTQ in the value of lanifibranor as a breakthrough therapy for patients suffering from MASH. The total proceeds from the financing will support the MASH program and subsequent filing for marketing approval, along with preparations for the potential commercialization of lanifibranor. I would also like to highlight the benefit Mark\u2019s deep expertise in the MASH field brings and look forward to working with him to ensure the best chance of getting lanifibranor to patients.<\/i>\u201d<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p><b>Dr. Nezam (\u201cNid\u201d) Afdhal, Chief of Gastroenterology, Beth Israel Deaconess Medical Center, Professor of Medicine, Harvard Medical School, said: <\/b><i>\u201cInvestigators and clinicians remain excited about the prospect of lanifibranor in MASH due to its effect on improving both fibrosis and resolution of MASH. PPAR agonism with lanifibranor has also been demonstrated to improve the metabolic profile and cardiovascular risk factors in our patients with MASH. This dual benefit has the potential to identify lanifibranor as an optimal choice for patients with MASH, significant fibrosis, and diabetes.\u201d<span class=\"Apple-converted-space\">\u00a0<\/span><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0Inventiva (Euronext Paris and Nasdaq: IVA) (\u201cInventiva\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (\u201cMASH\u201d) and other diseases with significant unmet medical needs, today announced financing of immediately \u20ac94.1 million and up to \u20ac348 million (the \u201cTransaction\u201d), subject to&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-89478","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Inventiva announces financing of up to \u20ac348 million to advance the NATiV3 Phase 3 MASH study - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inventiva announces financing of up to \u20ac348 million to advance the NATiV3 Phase 3 MASH study - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"\u00a0Inventiva (Euronext Paris and Nasdaq: IVA) (\u201cInventiva\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (\u201cMASH\u201d) and other diseases with significant unmet medical needs, today announced financing of immediately \u20ac94.1 million and up to \u20ac348 million (the \u201cTransaction\u201d), subject to...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-14T08:07:24+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Inventiva announces financing of up to \u20ac348 million to advance the NATiV3 Phase 3 MASH study\",\"datePublished\":\"2024-10-14T08:07:24+00:00\",\"dateModified\":\"2024-10-14T08:07:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/\"},\"wordCount\":571,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/\",\"name\":\"Inventiva announces financing of up to \u20ac348 million to advance the NATiV3 Phase 3 MASH study - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2024-10-14T08:07:24+00:00\",\"dateModified\":\"2024-10-14T08:07:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inventiva announces financing of up to \u20ac348 million to advance the NATiV3 Phase 3 MASH study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inventiva announces financing of up to \u20ac348 million to advance the NATiV3 Phase 3 MASH study - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/","og_locale":"en_US","og_type":"article","og_title":"Inventiva announces financing of up to \u20ac348 million to advance the NATiV3 Phase 3 MASH study - ANDERA PARTNERS","og_description":"\u00a0Inventiva (Euronext Paris and Nasdaq: IVA) (\u201cInventiva\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (\u201cMASH\u201d) and other diseases with significant unmet medical needs, today announced financing of immediately \u20ac94.1 million and up to \u20ac348 million (the \u201cTransaction\u201d), subject to...","og_url":"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2024-10-14T08:07:24+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Inventiva announces financing of up to \u20ac348 million to advance the NATiV3 Phase 3 MASH study","datePublished":"2024-10-14T08:07:24+00:00","dateModified":"2024-10-14T08:07:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/"},"wordCount":571,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/","url":"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/","name":"Inventiva announces financing of up to \u20ac348 million to advance the NATiV3 Phase 3 MASH study - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2024-10-14T08:07:24+00:00","dateModified":"2024-10-14T08:07:24+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/inventiva-announces-financing-of-up-to-e348-million-to-advance-the-nativ3-phase-3-mash-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Inventiva announces financing of up to \u20ac348 million to advance the NATiV3 Phase 3 MASH study"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/89478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=89478"}],"version-history":[{"count":1,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/89478\/revisions"}],"predecessor-version":[{"id":89479,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/89478\/revisions\/89479"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=89478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=89478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}